Table 2 Clinical, serological, and pharmacological treatments in patients with systemic lupus erythematosus: correlation with adenosine A_2A receptor affinity and density

 CQD/CAD

46/18

1.96 ± 1.19/1.77 ± 0.89

NS

141.6 ± 48.9/76 ± 28.6

< 0.0001

 Renal, yes/no

13/67

1.33 ± 0.59/1.94 ± 1.15

0.06

114 ± 45.05/120.8 ± 52.3

NS

 Neuropsychiatric, yes/no

20/60

1.73 ± 0.81/1.88 ± 1.18

NS

103.85 ± 48.2/125 ± 51.2

NS

 Articular, yes/no

46/34

1.79 ± 1.22/1.9 ± 0.9

NS

110.85 ± 49.3/131.8 ± 51.5

0.06

 Cutaneous, yes/no

25/55

1.46 ± 0.71/1.89 ± 1.2

NS

105.60 ± 43.9/123.8 ± 53.7

NS

 Hematological, yes/no

41/39

1.70 ± 0.89/1.98 ± 1.28

NS

116.85 ± 47.8/123.6 ± 54.5

NS

 Serositis, yes/no

21/59

1.60 ± 1.3/1.9 ± 0.9

NS

92.86 ± 38.7/129.2 ± 51.6

0.0043

 aCL, yes/no

22/58

1.91 ± 1.01/1.81 ± 1.14

NS

134.04 ± 52.55/114.27 ± 47.3

NS

 Anti-β₂-GPI, yes/no

9/71

1.59 ± 0.46/1.87 ± 1.15

NS

116.11 ± 53.15/120.2 ± 51.1

NS

 LA, yes/no

28/52

1.92 ± 1.20/1.8 ± 1.05

NS

109.03 ± 51.60/125.5 ± 50.2

NS

 ENA, yes/no

58/22

1.92 ± 1.15/1.77 ± 1.07

NS

114,5 ± 47.34/123.1 ± 53.52

NS

 Hypocomplementemia, yes/no

53/27

1.57 ± 0.78/2.15 ± 1.32

NS

97.88 ± 39.25/145.08 ± 51.78

< 0.0001

 Anti-dsDNA, yes/no

41/39

1.65 ± 1.01/2.31 ± 1.18

0.008

106.26 ± 48.42/153.04 ± 41.76

< 0.0001

 Corticosteroids, 2.5 up to 12.5 mg/day, yes/no

67/13

1.83 ± 1.17/1.88 ± 0.63

NS

113.12 ± 50.30/153.69 ± 41.47

0.0078

 Hydroxychloroquine, 200 mg/day, yes/no

48/32

1.93 ± 1.07/1.69 ± 1.13

NS

126.89 ± 51.09/108.93 ± 49.72

NS

 Immunosuppressants or induction therapy, yes/no

25/55

1.98 ± 1.19/1.54 ± 0.8

NS

124.31 ± 48.04/110.15 ± 56.46

NS

 Anticoagulants, yes/no

11/69

2.01 ± 1.47/1.81 ± 1.04

NS

128.91 ± 64.01/128.91 ± 64

NS

 Antiaggregants, yes/no

33/47

2.03 ± 1.24/1.7 ± 0.97

NS

123.39 ± 50.61117.13 ± 51.66

NS